Bone marrow stromal cells were found to up-regulate G6PD expression via interleukin-6 (IL-6) secretion, and targeting G6PD either pharmacologically or genetically could inhibit prostate cancer proliferation, migration, mesenchymal phenotype, and sensitivity to chemotherapy. Here, G6PD is linked to prostate carcinoma.